FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Monday

 

Study Shows Skin Problems Can Be Caused by Interferon-β MS Therapy

























Skin problems may be caused by interferon-β, a common treatment for multiple sclerosis (MS), according to a new study published by a German research group at the Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, in Würzburg, Germany. The work, entitled “Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis,” appeared July 2nd in the International Journal of Molecular Sciences.

MS can lead to serious health issues involving movement, sensation, vision and pain. These symptoms are due to an aggressive, uncontrolled immune response that the body launches against myelin, a fatty substance that wraps around nerve cells and helps them to communicate. One current approach to treating MS is to suppress a patient’s over-active immune system through the prescription of Interferon-β based therapies.

Interferons are normally produced by the immune system and have the ability to shut down immune reactions, which is more commonly known as inflammation. It is not precisely understood what role interferon plays in MS, but it is known that interferon-β can block inflammation in MS and help prevent the loss of myelin. Interferons are approved first-line therapies for MS.

Unfortunately, like many medications, side effects often accompany interferon-β treatment and must be weighed alongside their efficacy by both patients and their physicians.

Now, according to this new research, “although interferons are usually safe and well tolerated, they frequently cause dermatological side effects.”

Using a case study approach, the scientists studied an MS patient treated with interferon-β who developed new-onset psoriasis. Psoriasis is itchy, dry skin caused by the build-up of skin cells in patches. The researchers noted that “both her MS as well as her psoriasis finally responded to treatment with fumigates.”

Physicians who treat MS need to take possible skin reactions into consideration and endeavor to choose treatments based on whether or not an individual is susceptible to skin reactions.

The authors noted that, “in conclusion, we think that neurologists should be aware of systemic cutaneous side effects and have a closer look on interferon-associated skin lesions. Detection of psoriasiform lesions might indicate that interferons are probably not beneficial in the individual situation. We suggest that skin lesions may serve as biomarkers to allocate MS patients to adequate disease-modifying drugs.”

Neurologists should consider monitoring skin reactions and consider clinical information about skin conditions when selecting Interferon-β treatment for MS. Skin lesions may even cause MS patients to stop taking their medication. People who are vulnerable to developing psoriasis may not be good candidates for this medication.

In general, more disease modifying treatments with reduced side-effects are needed for the treatment of MS.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News